The Drug That Could Rewrite How We Treat the Most Common Blood Cancer

Why Moving to First-Line Is Such a Big Deal

In oncology, there's a massive commercial and clinical difference between being a third-line rescue drug and a first-line standard of care. Think of it like the difference between being a relief pitcher and a starting pitcher: the starting role means you see every game.

DLBCL is diagnosed in tens of thousands of patients each year, making it the most common type of aggressive lymphoma. When your drug is only approved for patients who've already failed multiple treatments, you're fishing in a small pond. Most patients are cured by R-CHOP and never need you.

But if you become part of the frontline regimen? Now you're treating nearly every newly diagnosed patient who walks through the door. The addressable market explodes overnight.

This is exactly why analysts at Jefferies have previously pegged epcoritamab as a potential $2.75 billion peak sales product. And that estimate may prove conservative if frontline adoption takes hold broadly.

The Numbers Tell a Growth Story

Epcoritamab is already on a tear commercially. In 2025, global net sales of Epkinly hit $468 million, a 67% jump from the prior year, and that was before this frontline data dropped.

Genmab, which co-develops the drug with AbbVie, recently raised its full-year 2026 revenue guidance to $4.325 to $4.525 billion, up from the prior range of $4.065 to $4.395 billion. Management credited the bump partly to Epkinly's growing momentum.

The commercial setup is also worth noting. AbbVie and Genmab split profits in the U.S. and Japan, while AbbVie handles the rest of the world. AbbVie's massive oncology sales infrastructure gives them the muscle to push this drug into hematology clinics globally, a distribution advantage that smaller biotechs simply can't match.

Roche Won't Go Quietly

Of course, AbbVie and Genmab aren't the only ones trying to crack frontline DLBCL with a bispecific antibody. Roche has its own CD20xCD3 bispecific, glofitamab (Columvi), and is running a Phase 3 trial called SKYGLO that pairs it with a different chemo backbone (Polivy plus R-CHP) in newly diagnosed DLBCL.

SKYGLO recently completed enrollment, so data could arrive within the next year or so. That sets up what could become one of the most consequential head-to-head commercial battles in hematology: two bispecific antibodies, both gunning for the same enormous patient population, backed by two pharma giants with deep pockets and global reach.

The key difference right now? AbbVie and Genmab have the data in hand. Roche is still waiting for theirs.

What Comes Next

AbbVie and Genmab said the full dataset will be presented at an upcoming medical meeting, where we'll get a closer look at safety details, duration of response, and subgroup analyses. A regulatory filing is the logical next step, and given the strength of the hazard ratio, approval odds look favorable.

The broader significance is hard to overstate. EPCORE DLBCL-2 is the first Phase 3 bispecific antibody combination trial to show a statistically significant improvement in progression-free survival in frontline DLBCL. No other bispecific has done this. For a disease where the standard of care hasn't meaningfully changed in decades, that's not just a clinical milestone; it's a potential paradigm shift.

R-CHOP has been the backbone of DLBCL treatment since the early 2000s. It's effective, it's cheap (especially now that rituximab has biosimilars), and oncologists know it inside and out. Dethroning it, or at least upgrading it, was never going to be easy.

But cutting the risk of progression in half? That's the kind of result that changes prescribing habits. And for the roughly one in three DLBCL patients who would have relapsed on R-CHOP alone, it might change everything.

Why Shionogi Just Bet $2 Billion on a Tiny Texas Biotech

Shionogi just agreed to pay $2 billion in cash for a tiny Texas biotech most people have never heard of. The reason? A first-in-class drug for two ultra-rare diseases and a pipeline that could reshape how we think about Japanese pharma's appetite for U.S. rare disease assets.